- Home
- IGIC vs PVLA Comparison
IGIC vs PVLA Comparison
Compare IGIC & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IGIC | PVLA |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | Jordan | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | IGIC | PVLA |
|---|---|---|
| Price | $25.23 | $133.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 17 |
| Target Price | $30.33 | ★ $154.59 |
| AVG Volume (30 Days) | 48.9K | ★ 355.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $34.82 | N/A |
| Revenue Next Year | $4.01 | N/A |
| P/E Ratio | $9.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.82 | $18.23 |
| 52 Week High | $27.63 | $151.18 |
Technical Indicators
Market Signals| Indicator | IGIC | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 53.72 | 68.31 |
| Support Level | $22.68 | $85.53 |
| Resistance Level | $25.54 | N/A |
| Average True Range (ATR) | 0.77 | 8.58 |
| MACD | -0.04 | 6.87 |
| Stochastic Oscillator | 36.09 | 73.74 |
Price Performance
Historical ComparisonAbout IGIC International General Insurance Holdings Ltd.
International General Insurance Holdings Ltd is an international specialist commercial insurer and a reinsurer, underwriting a diverse portfolio of specialty lines. The company operates in a portfolio of Energy, Property, Construction, Engineering, Ports and terminals, Financial Institutions, General Aviation, Professional Indemnity, Casualty, Directors and Officers, Political Violence, Forestry, and Treaty Reinsurance. Its operating segment includes Specialty Longtail; Specialty Short tail and Reinsurance.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.